表紙
市場調査レポート

中国の血液製剤産業

China Blood Product Industry Report, 2016-2019

発行 ResearchInChina 商品コード 210301
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
中国の血液製剤産業 China Blood Product Industry Report, 2016-2019
出版日: 2016年03月03日 ページ情報: 英文 150 Pages
概要

当レポートでは、中国の血液製剤産業について調査分析し、産業の概要、中国市場の動向、製品セグメント別の分析、主要企業、発展予測などについて、体系的な情報を提供しています。

第1章 血液製剤産業の概要

  • 定義
  • 分類
  • 組み換え血液製剤
  • 産業チェーン
  • 特徴

第2章 中国の血液製剤産業の概要

  • 市場規模
  • 現状
  • 需要と供給
  • 市場競合
  • 経営環境
    • 国際市場
    • 政策
    • 国内のバイオ医薬品市場
  • 輸出入

第3章 中国の血液製剤市場セグメント

  • ヒトアルブミン
  • 静脈注射ヒト免疫グロブリン
  • 血液凝固第VII因子
  • B型肝炎免疫グロブリン
  • ヒト免疫グロブリン
  • ヒトプロトロンビン複合体
  • 破傷風免疫グロブリン
  • 狂犬病免疫グロブリン

第4章 中国の主要メーカー

  • China Biologic Products Inc.
  • Hualan Biological Engineering Inc.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Beijing Tiantan Biological Products Co., Ltd.
  • Zhenxing Biopharmaceutical and Chemical Co., Ltd.
  • Jiangxi Boya Bio-Pharmaceutical Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Shanghai Institute of Biological Products Co., Ltd.
  • Shanxi Kangbao Biological Product Co., Ltd.
  • Green Cross
  • Humanwell Healthcare Group Co., Ltd.
  • Walvax Biotechnology Co, Ltd.

第5章 サマリーと予測

  • 企業分析
  • 予測

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: ZYM075

Recombinant blood products have developed for many years in foreign countries, but China's blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises. Amid the industrial prosperity and favorable policies, China had more than 190 plasma collection stations with the production-use plasma volume of 4, 700 tons and the total lot release volume jumped by 3.36 million bottles year on year to 55.76 million bottles in 2015.

Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry, contributing 61.9% to China's production-use plasma volume in 2015.

From the point of view of the product structure, human albumin is still the largest type of blood products in China, but its supply has slowed down with a lower contribution 58.8% to China's total blood product lot release volume in 2015. In recent years, the rising lot release volume of Chinese human albumin is mainly attributed to ample supply of imported products. In 2011-2015, the lot release volume of human albumin imported by China grew at a CAGR of 23.7%, accounting for as much as 55.6% of the total. China's top four human albumin import enterprises --- Behring, Baxter, Grifols and Octapharma seized 50.7% of the total lot release volume in 2015.

China's second largest type of blood products -- human immunoglobulin (ph4) for intravenous injection saw its lot release volume jump by 31.5% year on year to 9.4 million bottles (2.5g / bottle) and its share increase to 16.9% in 2015. Over the same period, tetanus human immunoglobulin, hepatitis B immune globulin and other immune globulin products and coagulation factor products witnessed growth in lot release volume except human rabies immunoglobulin whose lot release volume declined slightly.

The research and development of human blood coagulation factor VIII, human prothrombin complex and other small products in rigid demand has made the most remarkable progress in recent years. Concerning human blood coagulation factor VIII, Shanghai Xinxing had been approved to launched its human blood coagulation factor VIII, Shenzhen Weiguang had entered the new drug registration stage, Guangdong Shuanglin Bio-Pharmacy had embarked on trial production, Jiangxi Boya Bio-Pharmaceutical had gone into clinical phase III (the industrialization is expected in H2 2016), Wuhan Zhongyuan Ruide had obtained clinical approval and Harbin Pacific Biopharmaceutical had applied for clinical approval by the end of 2015.

In order to possess and effectively use plasma raw materials, enterprises are more willing to cooperate mutually in addition to acquisition. In August 2015, China Biologic Products and Xinjiang Deyuan signed a strategic cooperation agreement, under which the former should purchase at least 120/180/200 tons of plasma from the latter per year in the next three years. In 2015, Hebei Da'an Pharmaceutical and Guangdong Weilun actively planned to cooperate on the allocation of plasma fraction II + III, namely the former (it only produces human albumin now) should allocate partial plasma fraction II + III to Guangdong Weilun for the production of immunoglobulin products.

China Blood Product Industry Report, 2016-2019 focuses on the followings:

  • Market characteristics, operating environments, status quo, etc. of China blood product industry;
  • Supply and demand, competition pattern, import and export, development forecast, etc. of China blood product industry;
  • Supply and demand, competition pattern, etc. of 8 blood product segments, including human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor and tetanus human immunoglobulin;
  • Operation, blood product business and prospects of 13 major Chinese blood product companies.

image1

Table of Contents

1. Overview of Blood Product Industry

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 Recombinant Blood Products
  • 1.4 Industry Chain
  • 1.5 Features

2. Overview of China Blood Product Industry

  • 2.1 Market Size
  • 2.2 Status Quo
  • 2.3 Supply and Demand
    • 2.3.1 Supply
    • 2.3.2 Demand
  • 2.4 Competition
  • 2.5 Operating Environment
    • 2.5.1 International
    • 2.5.2 Policy
    • 2.5.3 Domestic Biopharmaceutical Market
  • 2.6 Import and Export

3. Blood Product Market Segments in China

  • 3.1 Human Albumin
    • 3.1.1 Supply and Demand
    • 3.1.2 Competition Pattern
    • 3.1.3 Prospects
  • 3.2 Human Immunoglobulin (pH4) for Intravenous Injection
    • 3.2.1 Supply and Demand
    • 3.2.2 Competition Pattern
  • 3.3 Blood Coagulation Factor VIII
    • 3.3.1 Supply and Demand
    • 3.3.2 Competition Pattern
    • 3.3.3 Prospects
  • 3.4 Hepatitis B Immunoglobulin
    • 3.4.1 Supply and Demand
    • 3.4.2 Competition Pattern
  • 3.5 Human Immunoglobulin
    • 3.5.1 Supply and Demand
    • 3.5.2 Competition Pattern
  • 3.6 Human Prothrombin Complex
    • 3.6.1 Supply and Demand
    • 3.6.2 Competition Pattern
  • 3.7 Tetanus Immunoglobulin
    • 3.7.1 Supply and Demand
    • 3.7.2 Competition Pattern
  • 3.8 Human Rabies Immunoglobulin
    • 3.8.1 Supply and Demand
    • 3.8.2 Competition Pattern

4. Major Chinese Manufacturers

  • 4.1 China Biologic Products Inc. (NASDAQ: CBPO)
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Customers and Suppliers
    • 4.1.5 R&D and Investment
    • 4.1.6 Shandong Taibang Biological Products Co., Ltd.
    • 4.1.7 Guizhou Taibang Biological Products Co., Ltd.
    • 4.1.8 Xi'an Huitian Blood Products Co., Ltd.
    • 4.1.9 Outlook and Prospects
  • 4.2 Hualan Biological Engineering Inc. (002007.SZ)
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 Customers and Suppliers
    • 4.2.6 R&D and Investment
    • 4.2.7 Blood Products
    • 4.2.8 Outlook and Prospects
  • 4.3 Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 Customers and Suppliers
    • 4.3.6 R&D and Investment
    • 4.3.7 Outlook and Prospects
  • 4.4 Beijing Tiantan Biological Products Co., Ltd. (TIANTANBIO, 600161.SH)
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Customers and Suppliers
    • 4.4.5 Gross Margin
    • 4.4.6 R&D and Investment
    • 4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)
    • 4.4.8 Outlook and Prospects
  • 4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd. (000403.SZ)
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 Customers and Suppliers
    • 4.5.6 R&D and Investment
    • 4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
    • 4.5.8 Outlook and Prospects
  • 4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (300294.SZ)
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 Customers and Suppliers
    • 4.6.6 R&D and Investment
    • 4.6.7 Outlook and Prospects
  • 4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
    • 4.7.1 Profile
    • 4.7.2 Blood Products
  • 4.8 Shanghai Institute of Biological Products Co., Ltd.
    • 4.8.1 Profile
    • 4.8.2 Blood Products
  • 4.9 Shanxi Kangbao Biological Product Co., Ltd.
    • 4.9.1 Profile
    • 4.9.2 Blood Products
  • 4.10 Green Cross
    • 4.10.1 Profile
    • 4.10.2 Blood Products
  • 4.11 Humanwell Healthcare Group Co., Ltd. (600079.SH)
    • 4.11.1 Profile
    • 4.11.2 Operation
    • 4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
  • 4.12 Walvax Biotechnology Co, Ltd. (300142.SZ)
    • 4.12.1 Profile
    • 4.12.2 Operation
    • 4.12.3 Blood Products (Hebei Da'an Pharmaceutical Co., Ltd. and Guangdong Weilun Biological Pharmaceutical Co., Ltd.)
  • 4.13 Shenzhen Weiguang Biological Products Co., Ltd.
    • 4.13.1 Profile
    • 4.13.2 Operation
    • 4.13.3 Revenue Structure
    • 4.13.4 Gross Margin
    • 4.13.5 Customers and Suppliers
    • 4.13.6 R&D and Investment
    • 4.13.7 Outlook and Prospects

5. Summary and Forecast

  • 5.1 Company Analysis
  • 5.2 Growth Prediction

Selected Charts

  • Basic Components of Blood
  • Plasma Protein Separation Procedure
  • Classification and Function of Blood Products
  • Comparison between Gene Recombinant Blood Products and Traditional Blood Products
  • Comparison between Domestic and Foreign Recombinant Blood Products in Types
  • Blood Product Industry Chain
  • Time Consumption of Plasma Collection and Separation Process
  • Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses
  • Prices of Some Blood Products in China, 2014
  • Blood Product Market Size in China, 2003-2015
  • Lot Release Volume of Blood Products in China (by Product), 2009-2015
  • Blood Product Structure in China (by Lot Release Volume), 2009-2015
  • Per Capita Frequency of Plasma Donation and Plasma Collection in China vs. the Occident
  • Plasma Collections in China vs. USA
  • Production-use Plasma Volume in China, 2008-2015
  • Number of Plasma Collection Stations in China, 2008-2015
  • Geographical Distribution of Plasma Station Resources in China by the End of 2015
  • Mainstream Blood Products with Medical Insurance Coverage in China
  • Per Capita Consumption of Blood Products in China vs. Developed Countries
  • Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2014
  • Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2015
  • Comparison of Chinese Blood Product Manufacturing Enterprises in Product Line
  • Competition Pattern of Global Blood Product Enterprises, 2013
  • Product Structure of Global Blood Products
  • Blood Products Available in Overseas Market
  • Global Blood Product Manufacturers
  • Main Policies on Chinese Blood Products
  • Policies on Maximum Retail Price of Drugs in China, 2014-2015
  • Lot Release Volume of Imported Human Albumin in China, 2008-2015
  • Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014
  • Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2015
  • Market Share of Major Human Albumin Manufacturers in China (by Lot Release Volume), 2008-2015
  • Consumption of Human Immunoglobulin (pH4) for Intravenous Injection per 1,000 Persons by Country, 2013 (g/1,000 persons)
  • Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2015
  • Price of Human Immunoglobulin (pH4) for Intravenous Injection in China vs. Other Countries
  • Average Purchase Price of Human Immunoglobulin (pH4) for Intravenous Injection of Sample Hospitals in China, 2005-2014
  • Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2015
  • Lot Release Volume and Growth Rate of Blood Coagulation Factor VIII in China, 2008-2015
  • Market Share of Major Human Blood Coagulation Factor VIII Manufacturers in China (by Lot Release Volume), 2008-2015
  • Comparison between Human Blood Coagulation Factor VIII and Recombinant Blood Coagulation Factor VIII
  • Per Capita Consumption of Recombinant VIII Factor and Plasma VIII Factor in Major Countries (IU/Person)
  • Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2009-2015
  • Market Share of Major Hepatitis B Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
  • Prices of Human Immunoglobulin in China by Dosage, 2014
  • Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2015
  • Market Share of Major Human Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
  • Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2008-2015
  • Market Share of Major Human Prothrombin Complex Manufacturers in China (by Lot Release Volume), 2008-2015
  • Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2015
  • Market Share of Major Tetanus Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
  • Rabies Incidents and Death Rate in China, 2008-2014
  • Lot Release Volume and Growth Rate of Human Rabies Immunoglobulin in China, 2008-2015
  • Market Share of Major Human Rabies Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
  • Equity Structure of China Biologic Products by the End of 2014
  • Distribution of Blood Products Manufacturing Bases and Plasma Stations of CBPO, 2015
  • Revenue and Operating Income of CBPO, 2008-2015
  • Gross Margin of CBPO, 2011-2015
  • Revenue Breakdown of CBPO (by Product), 2011-2015
  • Revenue Structure of CBPO (by Product), 2010-2015
  • CBPO's Revenue from Top 5 Customers and % of Total Revenue, 2008-2014
  • R&D Costs and % of Total Revenue of CBPO, 2010-2015
  • Lot Release Volume of Blood Products of Shandong Taibang Biological Products, 2008-2015
  • Lot Release Volume of Blood Products of Guiyang Qianfeng Biological Products, 2008-2015
  • Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2008-2014
  • Revenue and Operating Income of CBPO, 2014-2019E
  • Revenue and Operating Income of Hualan Biological Engineering Inc., 2008-2015
  • Revenue of Hualan Biological Engineering Inc. (by Sector), 2008-2015
  • Gross Margin of Hualan Biological Engineering Inc. (by Product), 2008-2015
  • Hualan Biological Engineering Inc.'s Revenue from Top 5 Customers and % of Total Revenue, 2007-2014
  • Hualan Biological Engineering Inc.'s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2014
  • Name List and Procurement Contribution of Hualan Biological Engineering Inc.'s Top 5 Suppliers, 2014
  • R&D Costs and % of Total Revenue of Hualan Biological Engineering Inc., 2008-2015
  • Types and Specifications of Blood Products of Hualan Biological Engineering Inc.
  • Distribution of Plasma Collection Stations of Hualan Biological Engineering Inc. by the End of 2015
  • Lot Release Volume of Blood Products of Hualan Biological Engineering Inc., 2008-2015
  • Revenue and Gross Margin of Blood Products of Hualan Biological Engineering Inc., 2008-2015
  • Revenue and Gross Margin of Blood Products of Hualan Biological Engineering Inc. (by Product), 2008-2015
  • Revenue and Operating Income of Hualan Biological Engineering Inc., 2014-2019E
  • Shanghai RAAS's Subsidiaries and Their Operation, H1 2015 (RMB mln)
  • Distribution of Plasma Stations of Shanghai RAAS by the End of 2015
  • Revenue and Operating Income of Shanghai RAAS, 2008-2015
  • Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2015
  • Lot Release Volume of Blood Products of Tonrol Bio-Pharmaceutical, 2008-2015
  • Operating Revenue of Shanghai RAAS (by Product), 2008-2015
  • Revenue of Shanghai RAAS (by Region), 2008-2015
  • Gross Margin of Shanghai RAAS (by Product), 2008-2015
  • Shanghai RAAS's Revenue from Top 5 Customers and % of Total Revenue, 2008-2015
  • Shanghai RAAS's Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2014
  • R&D Costs and % of Total Revenue of Shanghai RAAS, 2008-2015
  • Revenue and Operating Income of Shanghai RAAS, 2014-2019E
  • TIANTANBIO's Subsidiaries and Their Revenue and Income, H1 2015 (RMB mln)
  • Revenue and Operating Income of TIANTANBIO, 2008-2015
  • Revenue of TIANTANBIO (by Sector), 2008-2015
  • Revenue of TIANTANBIO (by Region), 2008-2015
  • TIANTANBIO's Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2014
  • TIANTANBIO's Revenue from Top 5 Customers and % of Total Revenue, 2008-2014
  • Gross Margin of TIANTANBIO (by Sector), 2008-2015
  • R&D Costs and % of Total Revenue of TIANTANBIO, 2009-2015
  • Distribution of Plasma Collection Stations of TIANTANBIO by the End of 2015
  • Revenue and Gross Margin of Blood Products of TIANTANBIO, 2008-2015
  • Lot Release Volume of Blood Products of RonSen and TIANTANBIO, 2008-2015
  • Revenue and Operating Income of TIANTANBIO, 2014-2019E
  • Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2008-2015
  • Operating Revenue of Zhenxing Biopharmaceutical and Chemical (by Product), 2009-2015
  • Gross Margin of Zhenxing Biopharmaceutical and Chemical (by Product), 2009-2013
  • Zhenxing Biopharmaceutical and Chemical's Revenue from Top 5 Customers and % of Total Revenue, 2009-2014
  • Name List and Revenue Contribution of Zhenxing Biopharmaceutical and Chemical's Top 5 Customers, 2014
  • Zhenxing Biopharmaceutical and Chemical's Procurement from Top 5 Suppliers and % of Total Procurement, 2014
  • R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical and Chemical, 2009-2015
  • Production-use Plasma Volume of Shuanglin Bio-Pharmacy, 2010-2015
  • Distribution of Plasma Collection Stations of Shuanglin Bio-Pharmacy by the End of 2015
  • Lot Release Volume of Blood Products of Shuanglin Bio-Pharmacy, 2008-2015
  • Revenue and Gross Margin of Blood Products of Zhenxing Biopharmaceutical and Chemical, 2009-2015
  • Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2014-2019E
  • Distribution of Single Plasma Collection Stations of Jiangxi Boya Bio-Pharmaceutical by the End of 2015
  • Plasma Collection Volume of Jiangxi Boya Bio-Pharmaceutical, 2008-2015
  • Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2008-2015
  • Revenue of Jiangxi Boya Bio-Pharmaceutical (by Product), 2009-2015
  • Lot Release Volume of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2011-2014
  • Operating Revenue of Jiangxi Boya Bio-Pharmaceutical (by Region), 2009-2014
  • Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2009-2015
  • Jiangxi Boya Bio-Pharmaceutical's Revenue from Top 5 Customers and % of Total Revenue, 2009-2015
  • Jiangxi Boya Bio-Pharmaceutical's Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2015
  • R&D Costs and % of Total Revenue of Jiangxi Boya Bio-Pharmaceutical, 2009-2015
  • Products under Research and Progress of Jiangxi Boya Bio-Pharmaceutical as of Oct. 2015
  • Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2014-2019E
  • Distribution of Plasma Stations of Sichuan Yuanda Shuyang Pharmaceutical by the End of 2015
  • Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2008-2015
  • Lot Release Volume of Blood Products of Shanghai Institute of Biological Products, 2008-2015
  • Distribution of Plasma Stations of Shanghai Institute of Biological Products by the End of 2015
  • Distribution of Plasma Stations of Shanxi Kangbao Biological Product by the End of 2015
  • Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2015
  • Distribution of Plasma Stations of Green Cross China by the End of 2015
  • Lot Release Volume of Blood Products of Green Cross China, 2008-2015
  • Revenue and Operating Income of Humanwell Healthcare, 2009-2015
  • Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Product, 2008-2015
  • Production Industry Layout of Walvax Biotechnology
  • Revenue and Operating Income of Walvax Biotechnology, 2009-2015
  • Revenue of Walvax Biotechnology (by Product), 2009-2015
  • Distribution of Single Plasma Collection Stations of Shenzhen Weiguang Biological Products by the End of 2015
  • Plasma Collection Volume and Production-use Plasma Volume of Shenzhen Weiguang Biological Products, 2012-2015
  • Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2012-2015
  • Capacity, Production and Sales Volume of Shenzhen Weiguang Biological Products (by Product), 2012-2015
  • Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (RMB mln)
  • Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (RMB mln)
  • Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2012-2015
  • Name List and Revenue Contribution of Shenzhen Weiguang Biological Products' Top 5 Customers, 2012-2015
  • Name List and Procurement Contribution of Shenzhen Weiguang Biological Products' Top 5 Suppliers, 2012-2015
  • R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2012-2015
  • Some Products under Research and Progress of Shenzhen Weiguang Biological Products by the End of 2015
  • Fundraising Projects of Shenzhen Weiguang Biological Products
  • Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2014-2019E
  • Number of Plasma Stations of Major Blood Product Enterprises in China as of Dec. 2015
  • Production-use Plasma Volume of Major Blood Product Enterprises in China, 2014-2015
  • Blood Product Revenue of Major Blood Product Enterprises in China, 2011-2015
  • Major M&A Events of Blood Product Industry in China, 2008-2015
  • Market Size of Blood Products in China, 2014-2019E
  • Gross Margin of Major Blood Product Enterprises in China, 2011-2015
Back to Top